Sanofi (France) and Rohto Pharmaceutical (Japan) are Leading Players in the Cold Pain Therapy Market
The global cold pain therapy market is projected to reach USD 2.4 billion by 2027 from USD 1.8 billion in 2022, at a CAGR of 5.1% during the forecast period. Growth in this market is mainly driven by the rising awareness about the availability of cost-effective cold pain relief products and the ease of application of cold pain therapy products. The increasing number of sports injuries & participation in sports and rising prevalence of arthritis.
The key players in this market are Beiersdorf AG (Germany), DJO Global, Inc. (US), Hisamitsu Pharmaceutical Co., Inc. (Japan), Össur (Iceland), Johnson & Johnson (US), Pfizer (US), Sanofi (France), Rohto Pharmaceutical (Japan), 3M (US), Cardinal Health Inc. (US), Bird & Cronin (US), Compass Health Brands (US), Breg, Inc. (US), Medline Industries (US), Performance Health (US), Romsons Group of Industries (India), Unexo Life Sciences (India), Polar Products (US), Rapid Aid (Canada), Mueller Sports Medicine (US), Pic Solution (US), Bruder Healthcare Company (US), Brownmed Inc. (US), Medichill (Australia), and ThermoTek, Inc. (US).
To know about the assumptions considered for the study download the pdf brochure
In 2021, Sanofi (France) held the leading position in the cold pain therapy market. The company has maintained a leading position in the market through its strong distribution networks across North America, Europe, the Asia Pacific, and Latin America. Sanofi has a strong direct and indirect distribution network across the globe. This helps in insulating its business from demand fluctuations in various geographies.
In 2021, Rohto Pharmaceutical (Japan) accounted for second-largest share of the cold pain therapy market. Rohto’s leading position in this market can be attributed to its strong global sales and distribution network, enabling it to effectively market its products in various countries. Also, Rohto has increased its focus on R&D activities to develop unique and better products than its competitors. Rohto’s investments in R&D to optimize its portfolio and capital allocation strategies help fuel its future growth and ability to remain competitive in the pain management market. In addition, Rohto’s strategies, which involve expansions, aim to further strengthen its position in the cold pain therapy market. In September 2019, the company announced the launch of an advanced technology research laboratory at the Hong Kong Science Park in New Territory, Hong Kong. This has helped the company significantly expand its product line and enhance its visibility in the market.
Related Reports:
Cold Pain Therapy Market by Product (OTC (Gels, Creams, Patches, Wraps, Pads), Prescription (Motorized, Non-motorized)), Application (Musculoskeletal, Post-Op, Sports Injuries), Distribution Channel (Hospital, Retail, E-Pharmacy) - Global Forecast to 2027
Contact:
Mr. Aashish Mehra
MarketsandMarkets™ INC.
630 Dundee Road
Suite 430
Northbrook, IL 60062
USA : 1-888-600-6441
[email protected]
This FREE sample includes market data points, ranging from trend analyses to market estimates & forecasts. See for yourself.
SEND ME A FREE SAMPLE
